WALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report second quarter 2021 financial results before the market opens on August 12, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management’s prepared remarks.
Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing 877-407-4018 (U.S.) or 201-689-8471 (international) or through the link
http://public.viavid.com/index.php?id=145976
. A replay of the call will be available from the Entasis website at
www.entasistx.com
following the call.
About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting
Acinetobacter baumannii
infections), zoliflodacin (targeting
Neisseria gonorrhoeae
infections), ETX0282CPDP (targeting
Enterobacteriaceae
infections) and ETX0462 (targeting
Pseudomonas
infections). For more information, visit
www.entasistx.com
.
Company Contact:
Kyle Dow
Entasis Therapeutics
(781) 810-0114
[email protected]
Investor Relations Contact:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
[email protected]
